MedTrace Logo

Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm

NCT06474533 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2026-04-03

No results posted yet for this study

Summary

This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.

Conditions

  • Intracranial Neoplasm

Interventions

DRUG

Fluorethyltyrosine (18-F)

Given intravenously (IV)

PROCEDURE

Positron Emission Tomography (PET)

Undergo Imaging Procedure

Sponsors & Collaborators

  • Thomas Hope

    lead OTHER

Principal Investigators

  • Javier Villanueva-Meyer, MD · University of California, San Francisco

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2028-08-31
Completion
2028-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06474533 on ClinicalTrials.gov